These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 9588734

  • 1. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC, Lau CS, Wong RW.
    Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
    [Abstract] [Full Text] [Related]

  • 2. Ovarian failure and flares of systemic lupus erythematosus.
    Mok CC, Wong RW, Lau CS.
    Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
    [Abstract] [Full Text] [Related]

  • 3. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
    Yang XY, Zhu X, Liang LQ, Zhan ZP, Ye YJ.
    Zhonghua Yi Xue Za Zhi; 2005 Apr 13; 85(14):960-2. PubMed ID: 16061002
    [Abstract] [Full Text] [Related]

  • 4. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ.
    Arthritis Rheum; 2005 Sep 13; 52(9):2761-7. PubMed ID: 16142702
    [Abstract] [Full Text] [Related]

  • 5. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC.
    J Rheumatol; 2002 Dec 13; 29(12):2571-6. PubMed ID: 12465154
    [Abstract] [Full Text] [Related]

  • 6. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
    Cunha I, Saavedra MJ, Pereira da Silva JA, Malcata A.
    Acta Reumatol Port; 2008 Dec 13; 33(1):69-76. PubMed ID: 18344924
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr 13; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 8. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
    Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM.
    J Rheumatol; 2002 Oct 13; 29(10):2129-35. PubMed ID: 12375322
    [Abstract] [Full Text] [Related]

  • 9. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
    Manger K, Wildt L, Kalden JR, Manger B.
    Autoimmun Rev; 2006 Apr 13; 5(4):269-72. PubMed ID: 16697968
    [Abstract] [Full Text] [Related]

  • 10. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
    Liang LQ, Qiu Q, Yang XY, Xu HS, Ye YJ, Zhan ZP, Lian F, Chen DY.
    Zhonghua Yi Xue Za Zhi; 2008 Apr 15; 88(15):1009-11. PubMed ID: 18754430
    [Abstract] [Full Text] [Related]

  • 11. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
    Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM.
    J Rheumatol; 2008 Sep 15; 35(9):1768-75. PubMed ID: 18634157
    [Abstract] [Full Text] [Related]

  • 12. Cyclophosphamide boluses induce micronuclei expression in buccal mucosa cells of patients with systemic lupus erythematosus independent of cytochrome P450 2D6 status.
    Aceves Avila FJ, Esquivel Nava GA, Gallegos Arreola MP, Gómez Meda B, Zúñiga González G, Ramos-Remus C.
    J Rheumatol; 2004 Jul 15; 31(7):1335-9. PubMed ID: 15229952
    [Abstract] [Full Text] [Related]

  • 13. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
    Mok CC, Chan PT, To CH.
    Arthritis Rheum; 2013 Jan 15; 65(1):206-10. PubMed ID: 23044647
    [Abstract] [Full Text] [Related]

  • 14. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
    Singh G, Saxena N, Aggarwal A, Misra R.
    J Rheumatol; 2007 Apr 15; 34(4):731-3. PubMed ID: 17407229
    [Abstract] [Full Text] [Related]

  • 15. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
    Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG.
    Arthritis Rheum; 2004 Jul 15; 50(7):2202-10. PubMed ID: 15248218
    [Abstract] [Full Text] [Related]

  • 16. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug 15; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 17. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K, Zintzaras E, Tzioufas AG.
    Clin Exp Rheumatol; 2010 Aug 15; 28(1):83-6. PubMed ID: 20346244
    [Abstract] [Full Text] [Related]

  • 18. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
    Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B.
    J Rheumatol; 2008 Jan 15; 35(1):100-5. PubMed ID: 17937462
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
    Zhang CY, Lu LJ, Li FH, Li HL, Gu YY, Chen SL, Bao CD.
    J Clin Rheumatol; 2009 Apr 15; 15(3):111-6. PubMed ID: 19300290
    [Abstract] [Full Text] [Related]

  • 20. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
    Tamirou F, Husson SN, Gruson D, Debiève F, Lauwerys BR, Houssiau FA.
    Arthritis Rheumatol; 2017 Jun 15; 69(6):1267-1271. PubMed ID: 28235250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.